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Abstract
For many years now there has been a growing frustration with the statistics of head and neck
cancer. Despite the many advances in diagnosis and therapy, there has been little change in the
prognosis for most cancers of the head and neck in the last 50 years, so what is the point of yet
another journal? Well, it is not all bad news.
Editorial
Standardisation of protocols and therapies have at least
ironed out some inconsistencies in the care delivered and
much of the work on quality of life issues has better
informed the process of treatment planning. Patients are
no longer willing to accept a treatment that has been rec-
ommended by an individual with intrinsic prejudices.
They need the facts about the impact of therapy on their
function and appearance as well as a realistic assessment
of their prognosis. Too often in the past, patients have
been offered extensive surgery as the only chance of a cure
when the survival statistics suggest these chances are very
slim.
These factors are of course applicable to many parts of the
world, but in underprivileged societies, the problems are
even more complex if there is no infrastructural support to
comprehensively treat those who suffer from cancer of the
head and neck.
Starting this new journal, Head & Neck Oncology, is an
undertaking that requires a conceptually clear vision of its
goals and distinctiveness from existing publications and
an intellectual involvement of Editorial Board members.
This is especially true in today's widely disseminated
media, which offer a broad menu of similar and often
overlapping topics. Head and neck oncology publications
have traditionally been surgically oriented due to the
dominance of the practice for these neoplasms. In the past
two decades, however, two major developments have
emerged that have fundamentally transformed the head
and neck cancer oncology field. One is the introduction of
adjuvant chemotherapy in advanced laryngeal cancer, and
the second is the successful use of concurrent chemo and
radiotherapy treatment in operable late stage patients. As
a result, multimodality concepts and demand for surro-
gate biomarkers have emerged as a dominant topic and
have led to an intense research in several fields. To this
end, the journal will provide a platform for articles from
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Head & Neck Oncology 2009, 1:1 http://www.headandneckoncology.org/content/1/1/1diverse subjects linking many head and neck areas for the
readers and contributing authors. To accomplish this, an
Editorial Board that represents a wide range of expertise in
different fields has been assembled and charged with the
responsibility to provide an efficient, balanced review
process, all with high standards for presentation to our
readers.
The realisation of the importance of multidisciplinary
team working has also had an impact on quality of life
issues. However, there still persists a divide between sur-
geons and radiation oncologists, not to mention medical
oncologists and allied health professionals. We intend to
bridge this gap by publishing, commissioning and solicit-
ing articles from all the personnel involved in the care of
head and neck cancer patients.
While Head & Neck Oncology will serve as a vehicle for
advances in squamous mucosal cancer, it will also present
topics from underserved and so-call "orphan tumors" of
the head and neck, including those of salivary gland, soft
tissue and skeletal neoplasms, endocrine, neuroendocrine
neoplasms, and the others that make head and neck
oncology arguably the most challenging of all oncology.
Another important focus of the journal will be the fields
of diagnostic and therapeutic biomarkers as a guide in
treatment of patients with surgically unresected, recurrent
and metastatic salivary gland, thyroid and sinonasal
tumors. Similarly, studies on the best practices and stand-
ardization of translational, biological, clinical practices
and quality assurance programs will be solicited and
encouraged. This diversity will serve readers with informa-
tion to minimize the variability of the diagnostic and clin-
ical staging within and across countries and continents. It
will also encourage the development of common basic
elements for clinical, pathological, and radiological
assessment of patients and the development of risk assess-
ment modules that advance and guide therapy. Banking,
standardization of harvesting, storing and transportation
of head and neck tumors and patient materials among
countries and continents is an emerging field of interest to
the journal. Studies in this field addressing these activities
are important for collaborative research multi-centre clin-
ical trials and correlative science. Likewise, rehabilitation
and functional outcome of head and neck cancer patients
are nascent but critical topics for the readers and inter-
ested contributors. The time has come for the develop-
ment and implementations of semi-quantitative and
objective measures to assess quality of life of these
patients, and the topic will be welcomed by the journal.
Our interests although not limited to, will include
Early diagnosis
Screening of high-risk groups with simple, semi auto-
mated techniques such as elastic scattering spectroscopy
has the potential to deliver a rapid accurate diagnostic
service. In the future, this might be offered outside the
conventional settings of a medical or dental practice. We
see this as being an exciting area of research that has
shown early promise although refinement will be neces-
sary to make the technology widely applicable.
Therapeutic advances
While some advances develop by a gradual process of evo-
lution and better tumour targeting; for example intensity
modulation and conformal radiotherapy – others happen
very rapidly by the application of new approaches. Photo-
dynamic therapy, for example, while first described over a
century ago is now licensed in the management of
advanced head and neck cancers in Europe and is an effec-
tive addition to our therapeutic arsenal. New chemother-
apy approaches with epithelial growth factor receptor
blockers such as Cetuximab have shown benefit in combi-
nation with radiotherapy and there are now many candi-
date compounds that are under investigation. We all await
the day when some "magic bullet" will leave us seeking
alternative employment, but to date, there have only been
tantalising glimpses of what might be. We will welcome
'tips and tricks' contributions that colleagues may have
developed which help them optimise care be it surgery,
radiotherapy, oncology...etc.
There is also a reluctance to accept new treatments in
mainstream clinical practice. Much of this conservatism is
a result of a paucity of level 1 evidence for almost any
treatment of head and neck cancer, especially surgical
studies. Funding for appropriately designed studies needs
to be secured to better dictate treatment decisions. Tradi-
tionally, this has proved difficult because head and neck
cancer typically (although not exclusively) affects the
older populations who smoke and drink alcohol. This
group are not the most vocal or articulate regarding their
condition and lack the emotional undertones of paediat-
ric malignancy, colon, breast and prostate cancer, which
are non-selective in terms of social class of the population
at risk. The formation of collaborative groups with suffi-
cient numbers to complete studies in a timely fashion has
economies of scale, but more importantly show a com-
mitment to serious research that should help funding.
Outcome measurements
Outcome is now a major factor dictating treatment deci-
sions and funding allocations. For patients suffering from
severe symptoms and/or side effects, quality of life out-
comes is every bit as important as survival rates. For exam-
ple, more targeted delivery of radiotherapy with maximal
shielding of salivary gland tissue becomes possible when
patients with radiation-induced xerostomia communicate
their feelings about which balance of survival rates and
being able to live without a dry mouth the treatmentPage 2 of 3
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should aim for. It is also an area in which speech and lan-
guage therapists and dieticians are able to quantify the
adverse effects of treatment. We will aim to avoid publish-
ing bias and support both positive and refuting research.
Treatment failure and Palliative Care
It is an unfortunate fact of life in head and neck cancer
that treatments may fail, and patients may require pallia-
tive care. However, clinicians have a lifelong commitment
to their patients and it is unreasonable to disengage and
merely refer patients to a hospice. The role of the clinical
nurse specialist is key throughout the patient journey, but
rarely more important than at the stage of disease recur-
rence. Patients may be offered any number of palliative
therapies and they will need help in deciding on exactly
what treatment is reasonable. This should be seamlessly
integrated with palliative care input and patients should
expect sufficient input to support their needs. Fear of
death is often associated with fear of the unknown or con-
cerns about pain control. Thanks to the pioneering work
of Dame Cicely Saunders and others, symptom relief has
developed to the stage where all palliative patients are
made comfortable and allowed to die with dignity.
It is our aim with this journal to encourage the interface
between all clinicians involved in management of head
and neck cancer with a truly multidisciplinary approach.
The next 10 years should be a fertile period in our very
specialised area of head and neck oncology.
Finally, there are many challenges that are ahead of us,
among which are to ensure high quality articles and orig-
inal studies in a competitive field, keeping pace with new
developments, discoveries and providing a timely and fair
review process. We hope that you will help support Head
& Neck Oncology and the future of this field.Page 3 of 3
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